Otsuka, Lundbeck Seek Alzheimer's Agitation Claim For Antipsychotic
Otsuka and Lundbeck are seeking to expand the use of psychiatry drug Rexulti into Alzheimer's agitation to up the product's commercial prospects, but mixed Phase III data for the drug mean a third regulatory nod is uncertain.
You may also be interested in...
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Lundbeck says it remains committed to developing new Alzheimer's disease drugs with a variety of different mechanisms, after the unsurprising failure of 5HT6 antagonist idalopirdine in two more Phase III studies.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.